AMGEN
LIVE

Serial Number

86834490

Owner

Amgen Inc.

Attorney

Elsa D. Lemoine

First Use Date

Jan 1, 1990

Filing Date

Nov 30, 2015

Add to watchlist:

No watchlists yet
View on USPTO

AMGEN Trademark

Serial Number: 86834490 • Registration: 6080333

AMGEN is a trademark filed by Amgen Inc. on November 30, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Amgen Inc. (18 trademarks)

One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Entity Type: 03

Trademark Details

Filing Date

November 30, 2015

Registration Date

June 16, 2020

First Use Anywhere

January 1, 1990

First Use in Commerce

January 1, 1990

Published for Opposition

August 16, 2016

Goods & Services

Providing healthcare administration, namely, providing insurance verification and prior authorization services for others

Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancer, chemotherapy and pharmaceutical products in the nature of medical referrals; business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals; providing an online commercial information directory in the field of patient support featuring information regarding healthcare providers, sites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations

Pharmaceutical research and development services; biological research; chemical research; medical research, namely, conducting clinical trials for others

Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors

Educational services, namely, development and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting seminars in the field of the use of prescription pharmaceutical products for medical disorders; educational and entertainment services, namely, providing a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email in the field of the treatment of medical disorders

Pharmaceuticals for the treatment of cardiovascular, cancer, bone, neurological nephrological and inflammation disease and disorders; pharmaceutical preparations for the treatment of anemia, ankylosing spondylitis, arthritis, cancer, cardiovascular conditions, collection by leukopheresis, effects of myelosuppressive chemotherapy, effects of myelosuppressive doses of radiation, glandular disorders, hormone disorders, hypercalcemia, hyperparathyroidism, hyperphosphatemia, kidney disorders and disease, migraine, neutropenia, osteoporosis, parathyroid disorders, psoriasis, reduction of red blood cell transfusions, renal disorders, thrombocytopenia; prescription pharmaceuticals for the treatment of anemia, ankylosing spondylitis, arthritis, cancer, cardiovascular conditions, collection by leukopheresis, effects of myelosuppressive chemotherapy, effects of myelosuppressive doses of radiation, glandular disorders, hormone disorders, hypercalcemia, hyperparathyroidism, hyperphosphatemia, kidney disorders and disease, migraine, neutropenia, osteoporosis, parathyroid disorders, psoriasis, reduction of red blood cell transfusions, renal disorders, thrombocytopenia; and pre-filled syringes and vials containing pharmaceutical preparations for the treatment of the aforementioned diseases and disorders and complications associated therewith

Patient support services relating to the treatment of medical disorders, namely, providing online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information services, namely, providing medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing information about bone health in patients with cancer by offering customized medical information and practical advice for communicating about bone health with healthcare providers; information services, namely, providing medical consultancy and advisory services via a global computer network in the field of cancer-related bone health; providing medical information and patient support services, namely, providing pharmaceutical advice and consultation in the nature of providing online information regarding bone health, the prevention of osteoporosis and the treatment and management of osteoporosis and bone disease, and pharmaceutical preparations for the treatment of osteoporosis; medical report services in the nature of providing medical reports regarding patients being treated for osteoporosis and bone disease; providing medical consultancy and advisory services via a global computer network in the field of cancer treatment and chemotherapy; providing medical information and patient support services, namely, pharmaceutical advice and consultation in the nature of providing online information regarding immune thrombocytopenic purpura; providing health and medical information about immune thrombocytopenic purpura; information services, namely, providing medical information to immune thrombocytopenic purpura patients; patient support services relating to treatment of medical disorders, namely, providing information to patients and families of patients in the field of administering medication, and patient medical information where patients can inquire about medical issues and procedures from medical personnel

Filing History

TEAS SECTION 8 & 15 RECEIVED
Jun 9, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 16, 2025 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 25, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 25, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 25, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 25, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 25, 2025 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 29, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 29, 2022 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 29, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 29, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 29, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 29, 2022 COAR
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 15, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 14, 2020 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 29, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 28, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 28, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 28, 2019 GNRN
NON-FINAL ACTION E-MAILED
Oct 28, 2019 GNRT
SU - NON-FINAL ACTION - WRITTEN
Oct 28, 2019 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Oct 12, 2019 SUPC
USE AMENDMENT FILED
Oct 10, 2019 IUAF
TEAS STATEMENT OF USE RECEIVED
Oct 10, 2019 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 4, 2019 EXRA
SOU EXTENSION 5 GRANTED
Apr 3, 2019 EX5G
SOU EXTENSION 5 FILED
Mar 28, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 28, 2019 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 7, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 7, 2019 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 11, 2018 EXRA
SOU EXTENSION 4 GRANTED
Sep 7, 2018 EX4G
SOU EXTENSION 4 FILED
Sep 7, 2018 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 7, 2018 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2018 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 16, 2018 EXRA
SOU EXTENSION 3 GRANTED
Mar 15, 2018 EX3G
SOU EXTENSION 3 FILED
Mar 13, 2018 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 13, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 13, 2017 EXRA
SOU EXTENSION 2 GRANTED
Sep 12, 2017 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 12, 2017 AITU
SOU EXTENSION 2 FILED
Aug 31, 2017 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 31, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 29, 2017 EXRA
SOU EXTENSION 1 GRANTED
Mar 27, 2017 EX1G
SOU EXTENSION 1 FILED
Mar 27, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 27, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 11, 2016 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2016 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 13, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 13, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 13, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 13, 2016 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 11, 2016 GNFN
FINAL REFUSAL E-MAILED
May 11, 2016 GNFR
FINAL REFUSAL WRITTEN
May 11, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 21, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 20, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 20, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 8, 2016 GNRN
NON-FINAL ACTION E-MAILED
Jan 8, 2016 GNRT
NON-FINAL ACTION WRITTEN
Jan 8, 2016 CNRT
ASSIGNED TO EXAMINER
Jan 7, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 4, 2015 NWOS
NEW APPLICATION ENTERED
Dec 3, 2015 NWAP